NTM Community (NTMinfo) is enthusiatic!!...Guess they are the REAL experts!!
The results of the clinical trial provide hope for NTM patients because this is the first drug to show efficacy against NTM in a clinical trial specifically designed to test it against the disease.
Additionally, this was a trial for patients who have already had standardized treatments which failed to convert their sputum to culture negative. The fact that in this study conversion to culture negative occurred rather quickly is very exciting, and the information thus far suggests that ARIKAYCE™ may be less toxic than intravenous Amikacin.
NTM Info & Research is greatly encouraged by the results of the ARIKAYCE™ study thus far, and we are hopeful that the medical community and industry will increase their focus on the diagnosis and treatment of NTM lung disease.